Search Results for "drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for drug. Results 2271 to 2280 of 2586 total matches.

Shingrix - An Adjuvanted, Recombinant Herpes Zoster Vaccine

   
The Medical Letter on Drugs and Therapeutics • Dec 04, 2017  (Issue 1535)
reserved. ©2017. www.fdbhealth.com/policies/drug-pricing-policy. 196 The Medical Letter ® Vol. 59 (1535 ...
The FDA has approved an adjuvanted, recombinant varicella zoster virus (VZV) vaccine (Shingrix – GSK) for prevention of herpes zoster (shingles) in adults ≥50 years old. Shingrix is the second herpes zoster vaccine to be approved in the US; Zostavax, a live-attenuated VZV vaccine approved for the same indication, has been available since 2006.
Med Lett Drugs Ther. 2017 Dec 4;59(1535):195-6 |  Show IntroductionHide Introduction

An EUA for Bamlanivimab and Etesevimab for COVID-19

   
The Medical Letter on Drugs and Therapeutics • Apr 05, 2021  (Issue 1621)
disease that requires daily drug treatment BMI = body mass index; COPD = chronic obstructive pulmonary ...
The FDA has issued an Emergency Use Authorization (EUA) for Lilly's investigational monoclonal antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) to be administered together for treatment of mild to moderate COVID-19 in patients ≥12 years old who weigh ≥40 kg and are at high risk of progressing to severe disease and/or hospitalization (see Table 1). Bamlanivimab received an EUA for use as monotherapy in such patients in November 2020. Regeneron's investigational monoclonal antibodies casirivimab (REGN10933) and imdevimab (REGN10987) are also authorized for use...
Med Lett Drugs Ther. 2021 Apr 5;63(1621):49-50 |  Show IntroductionHide Introduction

Monoclate: A Purified Antihemophilic Factor

   
The Medical Letter on Drugs and Therapeutics • Jan 01, 1988  (Issue 756)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Monoclate (Armour), a formulation of Factor VIII (antihemophilic factor; AHF) prepared by immunoaffinity chromatography, was recently approved for marketing by the US Food and Drug Administration. The new product is claimed to be more highly purified than older AHF formulations. Factor VIII concentrates commercially available in the USA are listed in the table below.
Med Lett Drugs Ther. 1988 Jan 1;30(756):1-2 |  Show IntroductionHide Introduction

Monoclonal For Gram-Negative Sepsis

   
The Medical Letter on Drugs and Therapeutics • Nov 01, 1991  (Issue 856)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
HA-1A (Centoxin - Centocor), a monoclonal IgM antibody against endotoxin from gram-negative bacteria, may soon be approved for marketing by the US Food and Drug Administration. Commercially available in Europe, HA-1A has been used in the USA as an investigational drug. E5 (Xomen - Xoma), another monoclonal IgM antibody against endotoxin, is also available here for investigational use.
Med Lett Drugs Ther. 1991 Nov 1;33(856):103-4 |  Show IntroductionHide Introduction

An Emergency Contraception Kit

   
The Medical Letter on Drugs and Therapeutics • Oct 23, 1998  (Issue 1038)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
High doses of estrogens, with or without a progestin, have been used for many years to prevent pregnancy after unprotected coitus (Medical Letter, 31:93, 1989). Now the FDA has approved marketing of the Preven Emergency Contraceptive Kit (Gynetics, Inc.) for this indication. The kit, which will require a prescription, includes four tablets, each containing 50 g of ethinyl estradiol and 0.25 mg of levonorgestrel, and a pregnancy test to rule out a pre-existing pregnancy, which would be a contraindication to taking the hormones.
Med Lett Drugs Ther. 1998 Oct 23;40(1038):102-3 |  Show IntroductionHide Introduction

Creatine and Androstenedione--Two "Dietary Supplements"

   
The Medical Letter on Drugs and Therapeutics • Nov 06, 1998  (Issue 1039)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Creatine, a natural amino acid derivative, and androstenedione, a testosterone precursor, are marketed as 'dietary supplements' in health food stores and are widely believed to enhance athletic performance. Both have been in the news recently because Mark McGwire, the baseball home-run record-setter, reportedly has said he takes both. Neither has been approved for any indication by the US Food and Drug Administration (FDA).
Med Lett Drugs Ther. 1998 Nov 6;40(1039):105-6 |  Show IntroductionHide Introduction

Tinzaparin, A Low Molecular Weight Heparin For Treatment of Deep Vein Thrombosis

   
The Medical Letter on Drugs and Therapeutics • Feb 19, 2001  (Issue 1098)
The Medical Letter  On Drugs and Therapeutics Published by The Medical Letter, Inc. • 1000 Main ...
Tinzaparin sodium, a low molecular weight heparin, has been approved by the FDA for treatment of acute deep vein thrombosis.
Med Lett Drugs Ther. 2001 Feb 19;43(1098):14-5 |  Show IntroductionHide Introduction

Zoledronate (Zometa)

   
The Medical Letter on Drugs and Therapeutics • Dec 10, 2001  (Issue 1120)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Zoledronic acid (Zometa), a new bisphosphonate, has been approved by the FDA for intravenous (IV) treatment of hypercalcemia of malignancy.
Med Lett Drugs Ther. 2001 Dec 10;43(1120):110-1 |  Show IntroductionHide Introduction

Beta Interferons for Multiple Sclerosis

   
The Medical Letter on Drugs and Therapeutics • Oct 14, 2002  (Issue 1141)
The Medical Letter  On Drugs and Therapeutics www.medicalletter.org Published by The Medical ...
Three beta interferons are widely used in the treatment of patients with relapsing-remitting multiple sclerosis (RRMS).
Med Lett Drugs Ther. 2002 Oct 14;44(1141):88-9 |  Show IntroductionHide Introduction

Blue light (ClearLight) for Acne Vulgaris

   
The Medical Letter on Drugs and Therapeutics • Jun 23, 2003  (Issue 1159)
The Medical Letter  On Drugs and Therapeutics www.medicalletter.org Published by The Medical ...
A high-intensity, narrow-band blue light (ClearLight -Lumenis) approved by the FDA for treatment of moderate inflammatory acne vulgaris has been featured in some stories in fashion magazines. This review describes the etiology and treatment of acne, as well as the mechanism of action, clinical studies, adverse effects, dosage and cost of the drug.
Med Lett Drugs Ther. 2003 Jun 23;45(1159):50-1 |  Show IntroductionHide Introduction